glutathione supplementation Youtheory Liposomal + Resveratrol Bundles:2 E11VEN Glutathione + FREE 1 Glowberry GHK Copper Peptide Skincare COPPER TRIPEPTIDE-1 (GHK-Cu) FOR

glutathione supplementation Youtheory Liposomal + Resveratrol Bundles:2 E11VEN Glutathione + FREE 1 Glowberry GHK Copper Peptide Skincare COPPER TRIPEPTIDE-1 (GHK-Cu) FOR

COPPER TRIPEPTIDE-1 (GHK-Cu) FOR SKIN, HAIR, LASH & BROW

Studies report modulation of NO synthase activity and interaction with NO-mediated tissue protection pathways, which may underlie its broad cytoprotective profile

GHK Copper Peptide Skincare

Bundles:2 E11VEN Glutathione + FREE 1 Glowberry

”‒ Peter Attia Even if the sequence is correct, the manufacturing process may differ in ways that are analytically important, and potentially clinically important When clinical trials show that a drug works They are not validating an amino acid sequence in the abstract They are validating a specific product, manufactured under specific processes, with a specific formulation and specific physiochemical characteristics The evidence applies to the product that was actually studied, not automatically to every preparation that shares the same amino acid sequence This is not mainly a regulatory argument It’s an acknowledgement that chemistry, manufacturing, and analytical science, are inseparable from pharmacology If you change the product, you may also change the properties of the drug Addressing the claim that pharmaceutical companies ignore effective natural peptides because they cannot be patented [A: 43:00, V: 41:26] How do you think about the statement: pharmaceutical companies can ignore these peptides because the natural peptides can’t be patented There’s only partial truth to that The kernel of truth is that you can’t patent a product of nature in its raw form, but patent law leaves enormous room for monetization—and this is the part people miss Almost none of these peptides exist in nature in the form that’s actually used Companies routinely patent modified analogs, new sequences, salts, conjugates, delivery systems, manufacturing processes, even specific dosing regimens and uses For example, Rapamycin, Metformin, and the statins all began as natural molecules and were all eminently patentable once modified Even BPC-157 has patents on all its salts and production methods Peter points out, “ The pharmaceutical industry is many things, but indifferent to money is not one of them .” Lack of pharmaceutical development doesn’t prove a peptide doesn’t work A reason to be skeptical Decades of promotion without convincing human efficacy data, despite obvious commercial interest, should lower your confidence that the claimed effects are as dramatic as advertised We’ve already seen exactly this dynamic play out A whole field of companies are racing to develop drugs built on synthetic variations of the same GLP-1 peptide biology—a drug based on a peptide found in nature So, if these gray market peptides truly delivered on their claims, that same pharmaceutical industry would be racing to develop them too And the conspicuous absence of that race should tell you what you need to know Something a lot of people don’t realize is that many of these wellness peptides are drugs that started in the pharmaceutical pipeline but stopped being pursued for one reason or another Inadequate efficacy, safety concerns, poor pharmacokinetics, a failure to outperform existing treatments, competition from a better drug, or simply the lack of commercially available indication The cleanest illustration of this is CJC-1295 versus tesamorelin Same underlying biology developed around the same time CJC-1295 reached phase 2 but was abandoned Tesamorelin advanced to phase 3 and received full FDA approval Tesamorelin is actually closer to the native molecule than CJC-1295 Its success has nothing to do with being more patentable or more natural It succeeded because the data were better The picture people have where peptides live in some world outside of the pharmaceutical industry is exactly backwards These molecules came from inside the industry, very often CJC-1295 is actually named after the pharma company that abandoned it, ConjuChem The gray market isn’t an alternative to pharma